Five Prime Therapeutics (NASDAQ:FPRX) Trading 5.5% Higher

Five Prime Therapeutics Inc (NASDAQ:FPRX) traded up 5.5% during mid-day trading on Thursday . The stock traded as high as $2.13 and last traded at $2.11, 169,046 shares changed hands during trading. A decline of 62% from the average session volume of 439,419 shares. The stock had previously closed at $2.00.

FPRX has been the topic of several research analyst reports. ValuEngine raised Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Zacks Investment Research raised Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday, March 3rd. Wedbush cut Five Prime Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $12.00 to $5.00 in a research note on Tuesday, February 18th. Finally, JPMorgan Chase & Co. cut Five Prime Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. Five Prime Therapeutics presently has an average rating of “Hold” and a consensus price target of $10.70.

The firm has a market cap of $72.78 million, a P/E ratio of -0.54 and a beta of 2.62. The company has a 50 day moving average of $3.48 and a 200 day moving average of $4.17. The company has a debt-to-equity ratio of 0.30, a quick ratio of 7.24 and a current ratio of 7.24.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Five Prime Therapeutics had a negative return on equity of 71.29% and a negative net margin of 922.43%. The firm had revenue of $3.21 million during the quarter, compared to analysts’ expectations of $4.05 million. As a group, analysts expect that Five Prime Therapeutics Inc will post -2.54 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Five Prime Therapeutics during the fourth quarter worth approximately $94,000. Cubist Systematic Strategies LLC raised its stake in shares of Five Prime Therapeutics by 106.4% in the fourth quarter. Cubist Systematic Strategies LLC now owns 22,818 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 11,764 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of Five Prime Therapeutics by 108.7% in the fourth quarter. California Public Employees Retirement System now owns 36,100 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 18,800 shares in the last quarter. Barclays PLC raised its stake in shares of Five Prime Therapeutics by 45.7% in the fourth quarter. Barclays PLC now owns 45,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 14,287 shares in the last quarter. Finally, Fred Alger Management LLC acquired a new position in shares of Five Prime Therapeutics in the fourth quarter valued at $230,000. Institutional investors own 72.10% of the company’s stock.

Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Featured Article: What is the price-to-earnings growth (PEG) ratio?

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.